Quetiron® XR Asino tablets are prescribed for the following indications:
active substance: quetiapine;
1 tablet contains 57.56 mg or 172.68 mg 345.36 mg quetiapine fumarate, which is equivalent to 50 mg or 150 mg or 300 mg quetiapine;
excipients: methacrylate copolymer (type A), lactose (SD 250), crystalline maltose (Advantose 100), talc, vegetable magnesium stearate;
shell composition: methacrylate copolymer (type A), triethyl citrate (Citrofol).
Hypersensitivity to the active substance or to any component of the preparation.
Concomitant use of cytochrome P450 3A4 inhibitors such as HIV protease inhibitors, azole antifungals, erythromycin, clarithromycin and nefazodone is contraindicated.
There are different dosing regimens for each indication. It should be ensured that the patient is prescribed dosages that are appropriate for his condition.
Quetiapine should be used once a day on an empty stomach. The tablets should be swallowed whole without breaking, chewing or crushing them.
Pregnant
During pregnancy, quetiapine can be prescribed only if the expected benefit outweighs the potential risk.
Children
Quetiapine is not recommended for use in children due to the lack of data to support its use in this age group.
Drivers
Given the main effect of quetiapine on the central nervous system, the preparation may interfere with activities requiring attention. Therefore, patients are not recommended to drive a car and use machinery until the individual sensitivity to such effects has been clarified.
In general, the signs and symptoms of overdose were the result of an increase in known pharmacological effects, such as drowsiness and sedation, tachycardia, arterial hypotension and anticholinergic effects. Overdose can lead to prolongation of the QT interval, convulsions, status epilepticus, rhabdomyolysis, respiratory depression, urinary retention, disorientation, delirium and / or agitation, coma, and death. Patients with existing severe cardiovascular disease may have an increased risk of overdose effects (see section "Peculiarities of use").
When taking quetiapine, the following adverse reactions were more often reported: drowsiness, dizziness, headache, dry mouth, mild asthenia, constipation, tachycardia, orthostatic hypotension and dyspepsia.
Caution should be exercised with the simultaneous use of quetiapine with preparations that disrupt the electrolyte balance or prolong the QT interval.
In patients receiving quetiapine, there were cases of false positive results of an enzyme immunoassay for the presence of methadone and tricyclic antidepressants. It is recommended that questionable immunoassay screening results be checked using an appropriate chromatographic method.
Store in original packaging, out of reach of children. Does not require special storage conditions.
Shelf life. 3 years.
There are no reviews for this product.